



January 5, 2021

RE: Clarification #2 for 2020-2021 Quality Assurance Reporting Requirements Technical Specifications

Dear Colleague,

This letter contains information about edits incorporated into the 2020-2021 Quality Assurance Reporting Requirements (QARR) Technical Specifications.

The information contained in this clarification has been incorporated into a revised version of the 2020-2021 QARR manual.

The updated 2020-2021 QARR Manual is posted on our Managed Care Information for Health Plans page. The revised specifications should be used in plans' processing for 2020-2021 QARR.

The following edits were made to the 2020-2021 QARR Specifications Manual:

- Added two measures to section 'New HEDIS Measures Added to NYS QARR List of Required Measures' (pg. 6).
- Well-Child Visits in the First 30 Months of Life (W30)
- Child and Adolescent Well-Care Visits (WCV)
Added section 'New Measures Added to NYS QARR List of Required Measures from Other Measure Stewards' (pg. 6); added new measure to this section.
- Annual Monitoring for Persons on Long-Term Opioid Therapy (AMO)
Edited CAHPS Files requirements in the Reporting Schedule section (pg. 23). Removed checks from MA/CHP, HIVSNP, and HARP products.

Table with 5 columns: Description, Deadline (June 15, 2021), Product List (CPPO, CEPO, CHMO, EP, MA/CHP, HIVSNP, HARP, QPPO, QEPO, QHMO, QPOS), Deadline (June 15, 2022), Product List (CPPO, CEPO, CHMO, EP, MA/CHP, HIVSNP, HARP, QPPO, QEPO, QHMO, QPOS).

- Edited the following in **Section V. AHRQ Quality Indicators in the Technical Specifications** (pg. 40-42).
  - **PDI Description**  
Pediatric Quality Indicators (PDI) overall composite per 100,000 enrollees, ages 6 to 17 years. Includes admissions for one of the following conditions: asthma, diabetes with short-term complications, gastroenteritis, or urinary tract infection.
  - **PDI Exclusions**
    - For a full list of inclusion and exclusion criteria see the Technical Specifications from AHRQ;  
[https://www.qualityindicators.ahrq.gov/Modules/PDI\\_TechSpec\\_ICD10\\_v2020.aspx](https://www.qualityindicators.ahrq.gov/Modules/PDI_TechSpec_ICD10_v2020.aspx)
  - **PQI Description**  
Prevention Quality Indicators (PQI) overall composite per 100,000 enrollees, ages 18 years and older. Includes admissions for one of the following conditions: diabetes with short-term complications, diabetes with long-term complications, uncontrolled diabetes without complications, diabetes with lower-extremity amputation, chronic obstructive pulmonary disease, asthma, hypertension, heart failure, dehydration, bacterial pneumonia, or urinary tract infection.
  - **Exclusions PQI**
    - For a full list of inclusion and exclusion criteria see the Technical Specifications from AHRQ;  
[https://www.qualityindicators.ahrq.gov/Modules/PQI\\_TechSpec\\_ICD10\\_v2020.aspx](https://www.qualityindicators.ahrq.gov/Modules/PQI_TechSpec_ICD10_v2020.aspx)
  - **Numerator PQI**
    - Removed PQI #10 Dehydration Admission Rate (effective v2019).
- Edited the **Technical Specifications Patient-Level Detail File Table** (pgs. 46-48).

	Measure Name	Specifications for Measures Included in the PLD NYS
AMO	Annual Monitoring for Persons on Long-Term Opioid Therapy	●
INR	International Normalized Ratio Monitoring for Individuals on Warfarin	●

- Edited location column for one measure in the **Summary-Level File Table** (pg. 50). Edited POD-N location to read 84-89.

Element	Location	Coding	Data Elements
POD-N Numerator	84-89	Right justified	Numerator events by administrative data.

- Edited the following NYS-Specific Behavioral Health Measure names in the **List of Required Measures (Table 1)** to align with the updates previously made to the NYS Technical Specification Measure Names (Table 1 pg. 18, Technical Specification pgs. 30-33).
  - Employed, Seeking Employment or Enrolled in a Formal Education Program
  - Stable Housing Status
  - No Arrests in the Past Year

If there are any questions about the above edits, or if you find issues or have concerns with the 2020-2021 Technical Specifications manual or the 2020 PLD specifications, please email [nysqarr@health.ny.gov](mailto:nysqarr@health.ny.gov).

Sincerely,

A handwritten signature in cursive script that reads "Paloma Luisi".

Paloma Luisi, MPH  
Director  
Bureau of Quality Measurement & Evaluation  
Division Quality Measurement  
Office of Quality and Patient Safety

CC: L. Cogan  
K. Egglefield